CD274 and breast cancer: Preclinical in vivo and in vitro breast cancer models have shown that PARP inhibition can upregulate PD-L1 by inactivating GSK3β, and that subsequent blockade of PD-L1 resensitizes PARP inhibitor-treated cells to T-cell killing [25].